9 December 2018 - The Trump administration has proposed several steps to address the cost of prescription drugs. Reaction mostly ranged from unimpressed to strong opposition. 

Rather than relying on bureaucratic micromanaging and price controls, we need to explore market solutions that expand access and encourage pharmaceutical innovation — and some are already here.

The good news is that the large majority of prescription drugs are very affordable. Generics, which are much less expensive copies of original brand-name drugs, represent nearly 90 percent of prescriptions sold in the U.S.

But some newer prescription drugs are expensive, and the primary reason is the cost of developing and moving them through the FDA’s approval process.

Read The Hill article